EXHIBIT 99.1 Net income was $24.3 million in the fourth quarter, or $0.20 diluted net income per common share, compared to net income of $30.7 million, or $0.26 diluted net income per common share, in the fourth quarter of 2024. For the full year, net income was $99.7 million, or $0.82 diluted net income per common share, compared to net income of $141.2 million, or $1.23 diluted net income per common share, in 2024. Cash and investments were $532.4 million at December 31, 2025, compared to $603.2 million a ...

NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October 31, 2024 and December 30, 2025, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 21, 2026. SO WHAT: If you purchased Corcept common stock during the Class P ...

Core Insights - Corcept Therapeutics Inc. (NASDAQ:CORT) is set to announce its quarterly earnings on February 24, 2026, with analysts predicting an earnings per share (EPS) of $0.33 and revenue of approximately $254.9 million [1][6] Financial Performance - CORT has a price-to-earnings (P/E) ratio of 36.73, indicating a strong investor willingness to pay for its earnings [3][6] - The company’s price-to-sales ratio stands at 5.29, reflecting the market's valuation of its revenue [3] - CORT's enterprise value to sales ratio is 5.13, slightly lower than its market capitalization relative to sales [3] Financial Health - The company exhibits strong financial health with a low debt-to-equity ratio of 0.01, indicating minimal reliance on debt [4][6] - CORT's current ratio is 3.14, suggesting it can adequately cover short-term liabilities with its current assets [4][6] - However, the enterprise value to operating cash flow ratio is 23.37, indicating a high valuation relative to cash flow from operations [4] Legal Challenges - CORT is facing a securities class action lawsuit filed by the Allegheny County Employees' Retirement System, which claims the company ignored FDA warnings about its lead product, relacorilant [2] - This lawsuit has resulted in a 50% drop in CORT's stock price, significantly affecting investor confidence [2] - Investors affected by the stock's decline are encouraged to contact the law firm Hagens Berman, with a deadline for lead plaintiff applications set for April 21 [5]

SAN DIEGO--(BUSINESS WIRE)---- $CORT #CORT--The lawsuit alleges that defendants failed to disclose that the FDA raised concerns about the adequacy of evidence supporting relacorilant's NDA. ...

NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northen District of California on behalf of all persons or entities who purchased or otherwise acquired Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT) securities between October 31, 2024, and December 30, 2025, inclusive (the “Class Period”). The Complaint alleges that Defendants represented that the k ...

Polen Capital, an investment management company, released its fourth-quarter investor letter for “Polen 5Perspectives Small Growth Strategy”. A copy of the letter can be downloaded here. The Polen 5Perspectives Small Growth Composite Portfolio returned -1.3% gross and -1.5% net of fees in the fourth quarter of 2025, compared to a 1.2% return of the Russell 2000 Growth Index. Following double-digit returns in 2Q and 3Q, small caps concluded the year with a 1.2% return in 4Q. Biotech stood out as a major per ...

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of common stock of Corcept Therapeutics Incorporated during the specified Class Period, indicating potential legal issues surrounding the company's stock performance and disclosures [1]. Group 1: Class Action Details - The class action lawsuit is on behalf of investors who purchased Corcept common stock between October 31, 2024, and December 30, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must be appointed by April 21, 2026, to represent other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked No. 1 for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [4]. Group 3: Case Specifics - The lawsuit claims that Corcept misrepresented the strength of clinical trials for relacorilant, suggesting it was a strong candidate for FDA approval, while the FDA had raised concerns about the clinical evidence [5]. - The defendants allegedly assured investors that there were no impediments to the New Drug Application (NDA) approval, which was later contradicted by the FDA's concerns [5]. - When the true situation regarding the NDA was revealed, investors reportedly suffered damages [5].

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC ("KSF†) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until April 21, 2026 to file lead plaintiff applications in a securities class action lawsuit against Corcept Therapeutics Incorporated (NasdaqCM: CORT) ("Corcept†or the "Company†), if they purchased or otherwise acquired the Company's shares between October 31, 2024 and December 30, 2025, inclusive (t ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Corcept (CORT) To Contact Him Directly To Discuss Their Options If you purchased or acquired Corcept common stock between October 31, 2024, and December 30, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- What’s Happeni ...

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Corcept Therapeutics Incorporated ("Corcept†or the "Company†) (NASDAQ:CORT) securities during the period of October 31, 2024 through December 30, 2025, inclusive ("the Class Period†). If you suffered a loss on your Corcept investments, you have until April 21, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff app. ...